The recipe for successful long-term investing is simple in theory but difficult in practice: Buy shares of high-quality companies; pay reasonable prices for those shares; and hold on to them for many years, unless there are legitimate reasons to sell. Failing at any one of those steps will cause trouble.
Any stock could double over the next decade, but only some have an above-average shot at doing so. These Motley Fool investors think following are these such stocks. Here’s what you need to know.
Top Growth Stocks To Buy For 2019: Clarke(T)
Telecom giant AT&T reported first-quarter earnings on April 26, and the market was none too pleased with the results. Sales for the period dipped 3.6% year over year to come in at $38.04 billion, missing the average analyst estimate of $39.37 billion. Earnings per share of $0.85 also fell short of the estimate target of $0.87, and the top- and bottom-line misses prompted the company’s biggest intraday share price decline in nearly a decade. By market close, the stock had dipped roughly 7%.
AT&T also reported that it lost 187,000 pay-television subscribers despite growth for its DirecTV Now skinny-bundle service. The company faces pressure amid changes in the television and mobile industries, but opportunities like the expansion of 5G networks and the pending merger with Time Warner give it avenues via which to growth that I expect will come to fruition. I purchased AT&T shares following the post-earnings sell-off and plan to hold the stock for the long term.
The company now trades at just 10 times this year’s expected earnings and packs a roughly 6% dividend yield. Shareholders can look for AT&T’s payout to continue growing. The telecom leader has a 33-year history of delivering annual dividend raises, and the business’s strong cash flow puts it in good position to deliver slow, but steady payout growth down the line. Even though the company distributed roughly $13 billion in dividend payouts over the last year, its $18 billion in free cash flow over that stretch had it in a good position to keep that streak alive.
With a great yield backed by a solid business and enticing earnings multiples, AT&T is an underappreciated dividend stock that deserves your attention.
Top Growth Stocks To Buy For 2019: AbbVie Inc.(ABBV)
Worry that its best-selling drug would soon face competition because of expiring patents may have caused you to remove AbbVie from your radar. However, the likelihood of competition to Humira has fallen considerably, and that suggests income investors ought to be looking at it again.
Humira is a widely used autoimmune disease drug. In 2017, its sales of more than $18 billion accounted for about 65% of AbbVie’s revenue. Patents protecting Humira have already begun to expire, but a favorable patent decision last fall prompted competitor Amgen (NASDAQ:AMGN) to ink a nonexclusive deal with AbbVie that should keep Humira copycats at bay in the U.S. until 2023.
The extra time is great news because AbbVie has a lot of late-stage drugs that could reach the market before Humira’s sales begin to drop. Over the next year, it plans FDA filings for Rova-T, a solid-tumor cancer drug; upadacitinib, a rheumatoid arthritis drug; and risankizumab, a psoriasis drug. All three of those drugs target multibillion-dollar indications and thus could be blockbusters.
AbbVie has FDA approvals pending for an endometriosis drug, Elagolix, and a chronic lymphocytic leukemia drug, Venclexta, that have billion-dollar potential, too.
The company has increased its dividend by 77% since it was spun out of Abbott Labs (NYSE:ABT) in 2013. Since management expects its effective tax rate to fall to 9% in 2018, from over 30% last year, and thinks new drugs could increase non-Humira sales from $9 billion to as much as $35 billion in 2025, there’s reason to think even more dividend increases are coming.
Top Growth Stocks To Buy For 2019: II-VI Incorporated(IIVI)
II-VI, Inc. (NASDAQ:IIVI) provides engineered materials and optoelectronic components worldwide.
The company’s total revenue reached $972 million as of fiscal year ending June 2017. This is 88.2% higher than the $516 million achieved in fiscal year June 2012. II-VI’s top-line growth has ranged from 6.7% to 24.0% over the last five fiscal years.
Going forward, Wall Street forecasts that II-VI’s total revenue will reach $1,839 million by fiscal year 2022 representing a five-year CAGR of 13.6%.
Shares of the company are up 23.0% over the last year. The stock last traded at $47.25 as of March 20th and 8 separate valuation analyses imply that the stock is trading near its fair value.